In vitro Effect of Bisphosphonates on Squamous Cell Carcinoma from Tongue Tissue

OCTAVIA IULIA BALEAN1*, ATENA GALUSCAN1, DANIELA JUMANCA1, CLAUDIA FARCAS2, DORINA CORICOVAC3, DOINA CHIORAN3, VOICHLTA LAZUREANU4*, ANGELA CODRUTA PODARIU4
1 University of Medicine and Pharmacy Victor Babes, Faculty of Dental Medicine, Department I, 14A Splaiul Tudor Vladimirescu, 300173, Timisoara, Romania
2 Victor Babes University of Medicine and Pharmacy, Faculty of Pharmacy, 2 Eftimie Murgu Sq, 300041, Timisoara, Romania
3 University of Medicine and Pharmacy Victor Babes, Faculty of Dental Medicine, Department II, 5 Take Ionescu, 300062, Timisoara, Romania
4 University of Medicine and Pharmacy Victor Babes, Faculty of Medicine, 2 Eftimie Murgu Sq, 300041, Timisoara, Romania

The purpose of this in vitro study was to evaluate the efficacy of three different types of bisphosphonates: Actonel (risedronate sodium), Fosamax (alendronic acid) and Ossica (ibandronic acid) on a squamous carcinoma cell line (SCC-4) with tongue tissue origin. The cell viability was assessed after a stimulation period of 24h and the Alamar Blue test was performed. The assessment revealed that the viability of squamous cell carcinoma was slightly reduced after treatment with the smallest concentration of bisphosphonates, with a lowest rate (89%) recorded for Actonel. When a concentration of 2 and 2.5 µM was used, the cell viability was between 85-89% independently of the type of bisphosphonates used. The higher concentrations of 3µM, 4µM showed a significant reduction of 72% when using Fosamax, and 68% when using Ossica. We can state that the viability of tongue squamous cell carcinoma cells decreases as the concentration of bisphosphonates used increases.

Key words: bisphosphonates, tongue squamous cell carcinoma, cell viability

Bisphosphonates have long become an integral part of the treatment of benign and malignant metabolic bone diseases, such as Paget’s disease, osteoporosis and tumour-associated hypercalcaemia and osteolysis, because of their ability to inhibit bone loss. Bisphosphonates are analogues of the naturally occurring inorganic pyrophosphate (PPi) in which the phosphate anhydride linkage (P-O-P) has been replaced by a non-hydrolysable P-C-P bond. Two covalently bound side chains (referred to as R1 and R2) at the central carbon atom give rise to a great variety of possible structures and contribute to their different relative potencies. Like their natural analogue, bisphosphonates are capable of binding divalent cations like Ca2+ in a tridentate manner, by coordination of the two phosphonate groups and the R1 substituent (preferably a hydroxyl group) [1-3].

The ability to chelate Ca2+ ions is the basis for the bone-targeting property of bisphosphonates, whereas the structure and stereochemistry of the R2 chain determines their efficacy to inhibit the activity of bone-resorbing cells (osteoclasts), leading to inhibition of bone resorption. Bisphosphonates can be grouped into two classes according to their mechanisms of action. Those with a simple R2 side chain lacking a nitrogen-containing functional group (such as clodronate) are metabolised intracellularly into non-hydrolysable ATP analogues that accumulate in the cytosol and subsequently induce apoptosis [1,2]. Nitrogen-containing bisphosphonates (N-BPs; such as pamidronate, risedronate or zoledronate), which are several orders of magnitude more potent in inhibiting bone resorption than their non-nitrogen counterparts, act on the mevalonate pathway by inhibiting the key enzyme farnesyl diphosphate synthase (FPP synthase), thereby depleting the cell of the isoprenoid lipids FPP and geranylgeranyl diphosphate (GGPP) [2,4].

Bisphosphonates represent a group of pharmacological agents that inhibit bone resorption, their main anti-osteolytic and antiangiogenic effects leading to their clinical applicability in various diseases. Currently, oral bisphosphonates are widely used in the treatment of bone metastatic disease (following malignant breast, prostate, lung or kidney tumours) or primary bone osteolytic pathology (multiple myeloma, Paget bone disease) or to alleviate the effects of hypercalcaemia in malignant diseases and pain associated with the osteolytic bone pathology [5].

The cumulative cytotoxicity of simple bisphosphonates inhibits bone resorption through osteoclast apoptosis. As bone resorption inhibitors, bisphosphonates have become the standard of care in the treatment of patients with bone metastases, however, it is now clear that bisphosphonates also have a both direct and indirect antitumour effect, this being demonstrated preclinically [2,6,7].

Bisphosphonates have demonstrated anticancer activity in vitro against a wide variety of tumour cell lines. The potency of several bisphosphonates to inhibit cancer cell proliferation and increase their apoptosis has been demonstrated in breast, prostate, ovarian, bladder, hepatic cancer, osteosarcoma, leukaemia, melanoma and myeloma cells [2]. Numerous studies have also described the ability of bisphosphonates to inhibit cancer cell invasion in vitro at micromolar concentrations [2,6,8,9]. However, the mechanism by which N-BPs induce apoptosis may...
vary depending on the type of cells and/or bisphosphonate used [10].

Studies reveal that bisphosphonates can act synergistically in combination with a variety of agents, resulting in improved cytotoxic activity in many different types of cancer cells. The use of drug combinations in cancer therapy has been established on the principle that these drugs may act synergistically (provide a greater benefit, in combination, compared to individual ones). There is preclinical evidence that the combination of bisphosphonates with chemotherapy drugs can lead to an improved antitumour treatment [2].

Oral bisphosphonates are widely used in the treatment of osteoporosis, and intravenous bisphosphonates are used in the treatment of bone metastatic disease or primary bone osteolytic pathology, or to alleviate the effects of hypercalcemia in malignant diseases and pain associated with the osteolytic bone pathology [5].

**Experimental part**

**Materials and methods**

Reagents and cell line

AlamarBlue - resazurin sodium salt and dimethyl sulfoxide (DMSO) reagents were provided by Sigma-Aldrich (Munich, Germany). All reagents were of analytical purity grade.

The cell line used in the present study, squamous cell carcinoma from tongue tissue - SCC-4 cell line (code no, ATCC CRL-1624) was acquired from American Type Culture Collection (ATCC) as frozen vial and stored in standard conditions (liquid nitrogen vapour phase).

**Cell culture**

SCC-4 cell line was cultured in specific growth medium: 1:1 mixture of Dulbecco’s Modified Eagle’s Medium and Ham’s F12 medium with L-Glutamine and HEPES (DMEM:F12, code no ATCC 30-2006) provided by ATCC. To obtain a complete growth medium the base medium was supplemented with the following components: 400ng/mL hydrocortisone commercially available, 10% FCS (fetal calf serum) and 1% antibiotics mixture of 0.1mg/mL streptomycin, 100U/mL penicillin (Sigma-Aldrich; Munich, Germany) to avoid a possible bacterial/fungal contamination during cell culturing.

Cell cultures were maintained under standard conditions, in humidified atmosphere with 5% CO₂ and a constant temperature of 37°C, in a Steri-Cycle i160 incubator (Thermo Fisher Scientific, USA).

Cell viability assessment

AlamarBlue (AB) assay is a well-known technique employed for cell viability assessment. The principle of this technique is based on a colorimetric reaction in which the dark blue resazurin salt is converted to resorufin, a pink compound, by the mitochondrial reductase of the viable cells. The optical density of the samples is directly proportional with the viable cell population.

In brief, 1x10⁴ cells/well were seeded onto 96-well plate, overnight. The following day, the medium from each well was replaced with a fresh one containing the test compounds to five different concentrations (1.5, 2, 2.5, 3, 4 µM) and the cells were incubated for 24h. Each concentration was tested in triplicate wells, as well the control cells (no stimulation -cells treated with growth medium). Upon completion of the stimulation period, 20µL/well of AB was added and after 4h, the mitochondrial reduction of the resazurin to resorufin was determined spectrophotometrically by measuring the absorbance of the wells at a wavelength of 570 nm and a reference wavelength of 600nm, with a microplate reader (xMark™ Microplate, Biorad). The wells without cells were used as negative control.

**Cell morphology assessment**

The cells were cultured in 6-well plates to an initial density of 1x10⁶ cells/well. When the optimal confluence (85-90%) was reached the old medium was replaced by a new one containing the test compounds at different concentrations (1.5, 2, 2.5, 3, 4 µM) and incubated for 24h. At the end of the incubation period the cells were photographed with an inverted microscope equipped with DP74 integrated camera (Olympus IX73, Tokyo, Japan) in order to observe the possible morphological alterations that could have occurred after the stimulation period had ended. The images were taken at magnification 20X.

**Results and discussions**

**Cell viability assessment**

In order to evaluate the influence of three different types of bisphosphonates (Actonel, Fosamax, Ossica) on squamous carcinoma SCC-4 cells’ viability after a stimulation period of 24h, the AB test was performed.

As presented in figure 1, the viability percentage of squamous carcinoma - SCC-4 cells was slightly reduced after 24h treatment with bisphosphonates (Actonel, Fosamax, Ossica) at concentration of 1.5 µM. Actonel induced the lowest proliferation rate, with a viability percentage of 89. However, stimulation with concentrations of 2 and 2.5 µM manifested almost the same activity on SCC-4 cell viability, the proliferation rate ranging between 85-89%, independently to the bisphosphonate structure. Nevertheless, higher concentrations of bisphosphonates (3 and 4µM) expressed a significant reduction of the squamous carcinoma SCC-4 cell viability, more intense after treatment with Fosamax and Ossica, representing a viability rate of 72 and 68%, respectively, in the case of the highest concentration (4µM). The solvent used to obtain bisphosphonates stock solution was DMSO and it was also tested for the possibility of inducing cytotoxic effect on SCC-4 cells. The results revealed only a slight inhibitory effect in the case of high concentrations (3, 4µM), showing a viability rate of 88.92% and 88.79%, respectively.

![Fig. 1. Squamous cell carcinoma (SCC-4) viability rate, after treatment with different concentrations of bisphosphonates (Actonel, Fosamax, Ossica) for 24h. The data are expressed as cell viability percentage (%) normalised to control cells (no stimulation). The results represent the mean values ± SD of three independent experiments. One-way ANOVA analysis was employed to determine the statistical differences followed by Tukey's post-test (* p <0.05; ** p<0.01; *** p<0.001 vs. Control)](http://www.revistadechimie.ro)
Morphologic aspects

Pictures of squamous cell carcinoma treated with bisphosphonates (Actonel, Fosamax, Ossica) at different concentrations (1.5, 2, 2.5, 3, 4 µM) were taken after 24h post-stimulation, in order to assess the effect of test compounds on SCC-4 cell morphology. The results are presented in figure 2.

According to the pictures displayed in figure 2, the morphology of control cells (no stimulation) presented epithelial-like characteristics, forming colonies and an adherent cell culture. After stimulation, the morphological characteristics of the cells were slightly affected by the treatment with the lowest concentration (1.5 µM) of bisphosphonates, however some morphological changes appeared when the concentration was increased, the cells manifesting irregular shape. Moreover, the cells stimulated with the highest concentration of bisphosphonates (4 µM) suffered major morphological alterations, displaying cell shrinkage. The results described for cell morphology evaluation are sustained by the ones obtained in the cell viability assessment, making our data consistent.

The innovation of this study refers to the use of squamous cell carcinoma from tongue tissue, and the use as stimulants of three types of bisphosphonates: Actonel (risedronate sodium), Fosamax (alendronic acid) and Ossica (ibandronic acid).

Four micromolar concentrations were used in the study. The results obtained showed that as the micromolar concentration increased, the viability of tongue squamous cell carcinoma cells decreased. An increased micromolecular concentration of bisphosphonates was inversely proportional to cell viability. It should be noted that the three types of bisphosphonates used can be given either by injection in the case of Ossica, and orally in the case of Fosamax and Actonel.

Kruger reported that low concentrations of Fosamax, from 5 µM to 20 µM, improved osteoblast proliferation, and at 100 µM concentrations it decreased osteoblast proliferation. [20] In the current study, the administration of Fosamax to tongue squamous cell carcinoma cells at low concentrations decreased less the viability compared to higher concentrations.

It is reported in the literature that osteosarcoma cells showed an increase in proliferation at low doses of bisphosphonates, while inhibition was observed at high doses, the same effect observed in this study for tongue squamous cell carcinoma cells [11].

In vitro, bisphosphonates containing nitrogen in their molecule inhibit the proliferation of osteoblasts having a direct and pro-apoptotic cytostatic action on tumour cells, as is also seen in this study [12].

The purpose of this study is to investigate the antitumour effect of bisphosphonates on tongue squamous cell carcinoma cells, but also to compare Actonel, Fosamax and Ossica, the three substances being used at different concentrations.

Conclusions

The viability of tongue squamous cell carcinoma cells decreases as the concentration of bisphosphonates used increases.

The results obtained showed a classification of the efficiency of the bisphosphonates used. The highest rate of cell viability decrease was due to the use of Ossica, followed by Fosamax and Alendronat.

In conclusion, we can say that bisphosphonates may have an in vitro antitumor action on tongue squamous cell carcinoma cell.
References
1. M. J. Rogers, J. C. Crockett, F. Coxon, Jukka Mönkkönen. Biochemical and molecular mechanisms of action of bisphosphonates. Bone Volume 49, Issue 1, July 2011, Pages 34-41
2. V. Stresing, F. Daubine, Ismahe'ne Benzaïd, Hannu Mönkkönen, P. Clézardin. Bisphosphonates in cancer therapy. Cancer letters Vol. 257, Issue 1, 8 November 2007, 16-35
3. R. Graham G., Russell. Bisphosphonates: The first 40 years. Bone Volume 49, Issue 1, July 2011, Pages 2-19
4. H. L. Neville-Webbe, M. Gnant, R. E. Colema. Potential Anticancer Properties of Bisphosphonates. Seminars in Oncology Volume 37, Supplement 1, June 2010, Pages S53-S65
5. Trandafir D., Trandafir V. Osteonecrosis maxilar de inducere de bifosfonate: Revista literaturii Jurnalul de chirurgie (Iasi), 2012, Vol 8 Nr.2 118-128
6. Clézardin P. Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Volume 12, Number 2, February 2012, pp. 102-113(12)
7. Brown H. K.; Holen, I. Anti-Tumour Effects of Bisphosphonates - What have we Learned from In Vivo Models? Current Cancer Drug Targets, Volume 9, Number 7, November 2009, pp. 807-823(17)
8. P. Clézardin. Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class. Bone Volume 48, Issue 1, January 2011, Pages 71-79
9. Berenson J. R. Antitumor effects of bisphosphonates: from the laboratory to the clinic. Current Opinion in Supportive and Palliative Care: September 2011 - Volume 5 - Issue 3 - p 233-240
10. M. Gnant, P. Clézardin. Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature. Cancer Treatment Reviews Volume 38, Issue 5, August 2012, Pages 407-415
11. Acil Y., Arndt ML, Gulses A, Wiekher H, Naujokat H, AyNA M, Wiltfang J. Cytotoxic and inflammatory effects of alendronate and zoledronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells. Journal of Cranio-Maxillofacial Surgery (2018), doi: 10.1016/j.jcms.2017.12.015.
12. Clézardin P. Bisphosphonates antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011 48:71-79

Manuscript received: 5.10.2018